Respimat
Respimat, commonly referred to as Respimat SMI (SMI indicates "Soft Mist Inhaler") is an advanced drug delivery device in comparison to MDIs (metered-dose inhalers) or DPIs (dry powder inhalers) used for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Its developer, Boehringer Ingelheim, is currently conducting Phase III clinical trials in the U.S. with a variety of their products, such as Spiriva (tiotropium bromde) and Combivent (ipratropium bromde/albuterol).
References
Sources
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-solution.jpg)
This article is issued from Wikipedia - version of the Tuesday, February 23, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.